) disclosed that it looked at AMG133's unblinded phase 2 interim trial and came away confident in 133's differentiated profile.
AMGN reported earnings after the close Friday, with analysts at Deutsche Bank stating that the company "notes 133's differentiation is relative to currently approved GLP1s and most importantly, those in the pipeline." "133 dominated the Q&A session and rightfully so, there's so much at stake and left to the imagination until 133's full Ph2 read out at year-end 24," stated Deutsche Bank.
Elsewhere, analysts at Barclays said they believe it's "far too early to really make any sort of conclusions" regarding the competitive profile of AMG 133.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Costco Offers Weight Loss Program with Medications from Eli Lilly and Novo NordiskCostco partners with Sesame to provide a weight loss program to members, offering medications like Ozempic and Wegovy. Members can receive three months of clinical consultation and other services for $179.
Source: FoxBusiness - 🏆 458. / 53 Read more »
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trialsThe pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Source: NBCPhiladelphia - 🏆 569. / 51 Read more »
Stocks making the biggest premarket moves: Eli Lilly, Travelers, United Airlines, Alcoa and moreThese are the stocks posting the largest moves in the premarket.
Source: CNBC - 🏆 12. / 72 Read more »
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA saysThe insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Source: CNBC - 🏆 12. / 72 Read more »
Eli Lilly's weight loss drug reduces sleep apnea, study showsEli Lilly noted that tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults that have both obstructive sleep apnea and obesity.
Source: FoxBusiness - 🏆 458. / 53 Read more »